← Leaderboards
Tere M. Williams
Dub Therapeutics Inc.
$2,809,211
Attributed
$2,809,211
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.1M · FY2023–25$2M$1.5M$1M$500K$0
'23
'24
'25
Funding mix
By agency
NIH$2,809,211 · 2
By mechanism
R44$2,809,211 · 2
Top collaborators
No co-investigators on record.
Others in their field
Other Rising Stars on “In Vivo”
- Michael Difilippantonio · Leidos Biomedical Research, Inc.$22,364,766
- Sabrina Paganoni · Massachusetts General Hospital$17,050,216
- Suma Babu · Massachusetts General Hospital$17,050,216
- Kevin V Grimes · Stanford University$14,783,804
- Xuping Xie · University Of Texas Med Br Galveston$13,737,799
- Heinz Ernst Moser · University Of Texas Med Br Galveston$12,973,432
Research focus
In VivoNucleaseFibroblastsInvestmentsManufacturing ProcessManufacturing Scale-UpEpitheliumFamily SuidaeGlaucomaDefectEncapsulatedKnock-DownCorneaManufacturing RunAffectBlindnessCicatrixExperimental StudyDoseFundingCyclic GmpCholesterolEfficacy StudyOryctolagus Cuniculus
Grant awards (4)
A novel siRNA therapeutic to prevent scarring and bleb failure after trabeculectomy$1,009,285
R44 · FY2025 · EY · contact PI
A single dose anti-scarring therapeutic for the cornea$917,935
R44 · FY2024 · EY · contact PI
A single dose anti-scarring therapeutic for the cornea$182,000
R44 · FY2024 · EY · contact PI
A single dose anti-scarring therapeutic for the cornea$699,991
R44 · FY2023 · EY · contact PI